It has a neurotrophic effect, inhibits apoptosis, limiting the affected area and restores the structure of nervous tissue. It normalizes the protein and fat metabolism, increased basal metabolism in hyperthyroidism (being a partial antagonist of thyroxine). The drug restores the blood alkaline reserve, does not affect blood clotting, omnadren 250 results reduces the formation of keto acids, increases the resistance of tissues to the effects of toxic degradation products, activates aerobic processes and inhibits anaerobic glycolysis, has anti-hypoxic properties, stimulates and accelerates the repair processes.Acute stroke – ischemic stroke, transient ischemic attack – in the acute, subacute and recovery period.Encephalopathy.Traumatic and toxic brain damage.As monotherapy or in combination therapy.
Dosage and method of administration
The drug is administered intravenously slowly (no more than 60 drops per minute). Before introducing the contents of one or two ampul- 5.10 ml of 10% solution of carnitine chloride (0.5-1 g) – diluted in 200 ml 0.9% sodium chloride solution for injection. In acute cerebrovascular disorders designate the first three days to 1 g once a day, and then for 7 days to 0.5 g per day. After 10-12 days of refresher courses are recommended – 0.5 g once a day for 3-5 days.
In appointing the drug in the subacute omnadren 250 results and recovery period, with vascular encephalopathy, and various brain lesions of patients administered by 0.5-1 r (1-2 ampoules) of the drug once a day for 3-5 days. If necessary, after 12-14 days, appoint a second course.
Allergic reactions are possible.
Patients with uremia possible muscle weakness.
With the rapid introduction (80 drops per minute or more) may cause pain along the vein passing while reducing the rate of administration.
Cases of overdose are unknown.
Interaction with other drugs
Glucocorticoids when combined with carnitine chloride contribute to its accumulation in the tissues (except liver).
Other anabolic agents enhance the effect.
Pregnancy and lactation
Specific studies of the possibility of the use during pregnancy and breastfeeding period is not carried out. The decision to use should be taken when evaluating potential hazard ratio for the child and the benefit for the mother.
Method of issuance:
. The vials of 5 ml
5 vials in blisters, 1 or 2 blisters in a cardboard pack.
Carnitine chloride solution for injection should be stored out of the reach of children and protected from omnadren 250 results light at a temperature not exceeding 25 ° C.
Do not use the drug after the expiry date!
Conditions of supply.
According to the recipe.